期刊
CLINICAL COLORECTAL CANCER
卷 18, 期 2, 页码 133-140出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clcc.2019.01.005
关键词
Chemotherapy; First-line therapy; Health outcomes; Metastatic cancer; Survival
类别
资金
- National Cancer Institute [NCI R01CA169121-01A1, NCI R01 CA166084]
- Breast Cancer Research Foundation/Conquer Cancer Foundation
An examination of the demographic and clinical characteristics associated with the use of folinic acid, fluorouracil, and oxaliplatin (FOLFOX) or leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRI) in patients with stage IV colon cancer found that FOLFOX is prescribed much more frequently than FOLFIRI as first-line therapy, especially in those who were female and those with fewer comorbidities. FOLFOX use has been increasing recently. Background: Shortly after the year 2000, randomized trials demonstrated that patients with metastatic colon cancer treated with infusional 5-fluorouracil (5-FU)/leucovorin with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) had a comparable progression-free survival benefit, superior to patients who received 5-FU/leucovorin alone. Factors associated with the initial receipt of the FOLFOX or FOLFIRI regimen are unknown. Our goal was to investigate the patterns and predictors of use for first-line FOLFOX and FOLFIRI. Patients and Methods: We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data set to identify patients with newly diagnosed stage IV colon cancer between the years 2005 and 2013 who received either first-line FOLFOX or FOLFIRI. We used logistic regression to assess demographic and clinical predictors for FOLFOX versus FOLFIRI. Survival was compared by Kaplan-Meier models. Results: Overall, 3000 patients (79.3%) received FOLFOX and 785 (20.7%) FOLFIRI. FOLFOX was associated with later year of diagnosis (odds ratio [OR] - 0.66, 95% confidence interval [CI], 0.54 to 0.82 for 2011-2013 vs. 2005-2007), being female (OR - 0.82; 95% CI 0.69 to 0.98), and living in the southern region of the United States. FOLFIRI was associated with having a higher comorbidity index (OR - 1.33; 95% CI, 1.07 to 1.67 for >1 comorbidity score vs. 0). There was no survival difference observed between the two treatments. Conclusion: The majority of SEER-Medicare patients received FOLFOX and not FOLFIRI as a first-line treatment for stage IV colon cancer. Several demographic and clinical factors were associated with the use of each specific regimen. No survival difference was detected for the 2 groups. (C) 2019 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据